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Abstract 
Among the human genome, p53 is one of the first tumor suppressor genes to be discovered. 
It has a wide range of functions covering cell cycle control, apoptosis, genome integrity 
maintenance, metabolism, fertility, cellular reprogramming and autophagy. Although different 
possible underlying mechanisms for p53 regulation have been proposed for decades, none of 
them  is  conclusive.  While  much  literature  focuses  on  the  importance  of  individual 
post-translational modifications, further explorations indicate a new layer of p53 coordination 
through the interplay of the modifications, which builds up a complex ‘network’. This review 
focuses  on  the  necessity,  characteristics  and  mechanisms  of  the  crosstalk  among 
post-translational modifications and its effects on the precise and selective behavior of p53. 
Key  words:  p53;  post-translational  modification;  crosstalk;  protein-protein  interaction;  semiotic 
system. 
Introduction 
Since the discovery of p53 in 1979 [1-3], numer-
ous studies have been conducted related to its func-
tions and regulatory mechanisms. Previous research 
has confirmed that p53 is able to coordinate a regula-
tory network that supervises and responds to a vari-
ety  of  stress  signals.  These  signals  include:  DNA 
damage, aberrant oncogenic activation, telomere ero-
sion, ribosomal stress, loss of cell-cell or cell-matrix 
adhesion, and hypoxia [4]. Regulating a vast pool of 
external  stimuli,  p53  exerts  irreplaceable  an-
ti-neoplastic  functions  at  homeostasis  and  thus  is 
considered  to  be  'the  guardian  of  the  genome‘  [5]. 
Mutations of p53 or disruptions of p53 coordination, 
to a lesser extent, can disturb the normal physiological 
balance, and lead to cancer if genome disarrangement 
reaches a critical value. 
Basic  elements  of  the  p53  coordination  are  its 
cellular localization, oligomerization [6] and concen-
tration, which are tightly and exquisitely interrelated. 
Originally, p53 was thought to perform its functions 
in its tetrameric form in the nucleus by acting as a 
transcription factor or as a binding partner [7-10]. At 
homeostasis,  the  transcriptional  activity  of  p53  is 
downregulated in three ways: 1. Ubiquitin-mediated 
proteasomal  degradation  of  p53  in  both  cytoplasm 
and  nucleus  mainly  through  mouse  double  minute 
protein 2 (Mdm2) [11]; 2. Decrease in nuclear p53 lev-
els through nuclear export by either the exposure of 
its nuclear export sequence (NES) [12, 13] or the NES 
of  Mdm2  [14];  and  3.  Transcriptional  repression  of 
chromatin-associated p53 by Mdm2-Mdmx-p53 com-
plex formation [15-17]. 
Under stress, degradation and nuclear export of 
p53  are  suppressed,  and  nuclear  import  of  p53  is 
concomitantly enhanced, resulting in its nuclear ac-
cumulation.  Recently  proposed  is  another  process 
involved  in  the  activation  of  chromatin-bound  p53 
termed as ‗anti-repression‘ [18]. Transcriptional levels 
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of p53 downstream target genes can be generally in-
creased by p53 nuclear accumulation and the release 
of chromatin-bound p53 from repression state. On the 
other hand, selective functions of p53 can be fulfilled 
through enhancement of p53‘s transactivation of spe-
cific target genes [19]. Although p53 primarily acts as 
a  transcription  factor,  a  transcription-independent 
role of cytosolic p53 to trigger apoptosis and inhibit 
autophagy  has  also  been  discovered  [20-22].  Re-
searchers  during  the  past  decades  have  discovered 
that,  in  either  the  homeostatic  maintenance  or 
stress-induced  activation  of  p53,  covalent  modifica-
tions play pivotal roles (summarized in Figure 1).  
Although  relatively  unified  findings  related  to 
the  functions  of  post-translational  modifications 
(PTMs)  were  obtained  in vitro,  the  in vivo  data  are 
somehow contradictory, indicating a variable behav-
ior  of  p53.  This  variability  is  characterized  by  cell 
type-  and  tissue-dependent  [23,  24],  genotype  and 
stimuli-specific responses [25-27]. 
 
 
Figure 1. Overview of p53 posttranslational modifications. The major domains of p53 and their distributions are depicted and 
only the modifications directly responsible for the listed effects are plotted. The modification sites within p53 are primarily updated from 
W Gu [164, 165].  
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The stimuli-specific response has received inten-
sive investigations, for it provides a potential model 
to study the discriminative behavior of p53 pathway. 
The  prominent  features  of  the  stimuli-specific  re-
sponses are distinct elevation manners and different 
gene expression profiles [28]. Because the concentra-
tion of p53 is tested indirectly by the antibody, Dif-
ferences in the elevation manner of p53 can be partly 
explained by the occupation of p53 antibody binding 
epitopes by PTMs. Different gene expression profiles 
is confirmed to be a result of combinatorial expression 
of specific sets of p53 target gene. This can be accom-
plished either through the promoter selection by p53 
or  the  dissimilar  assembly  manner  of  transcription 
complexes  by  chromatin-bound  p53  [29].  Promoter 
selectivity is attributed to different binding affinities 
for different response elements (REs) [30], presumably 
due to PTM marks on p53 [31-33]. Likewise, different 
assembly manners of transcription complexes, such as 
chromatin  remodelers,  histone  modifiers  or  RNA 
polymerase, can also be ascribed to p53 modifications 
[34, 35]. It is important to note that different types of 
stresses can result in different sets of modifications, 
which  bolsters  the  relationship  between  covalent 
modifications and the variability of p53 response [36, 
37]. 
Overall, PTM exerts both general and distinctive 
role in regulating p53 behavior. However, the contra-
dictions between the results of the in vitro and in vivo 
experiments call for more in-depth studies and raise 
some open problems concerning the real regulatory 
network of PTMs. 
The behavior of individual modifications 
p53 harbors an array of amino acids subject to 
various  kinds  of  PTMs,  which  are  mainly  concen-
trated  in  the  tetramerization  domain  (TD)  and 
C-terminal  domain  (CTD).  The  earliest-discovered 
behavior of individual modifications of p53 is the re-
dundancy of many N-terminal and C-terminal modi-
fications  [18],  which  is  characterized  by  either  the 
flexible  correspondence  between  the  enzymes  and 
modifications, or the subtle effects by the mutation of 
single site  [38]. This can be explained by either the 
complementarity among the modifications, or an ad-
ditive  and  synergistic  performance  of  the  modifica-
tions. Both mechanisms illustrate the significance of 
the crosstalk among the modifications. 
There  also  exist  switch-like  behaviors  of  indi-
vidual sites. The individual modifications involved in 
the  transactivation  by  p53  reflect  this  behavior,  of 
which the most scrutinized is acetylation. As an ex-
ample,  lysine  320 (K320) acetylation  is  necessary  in 
antagonizing  apoptotic  activity  of  p53  [39];  in  con-
trast, acetylation of K373 and K120 dominantly favors 
the activation of proapoptotic genes [31, 40]. Besides 
the  acetylation,  serine  46  (S46)  phosphorylation  is 
found to play critical roles in p53-mediated proapop-
tic gene induction but not in the induction of cell-cycle 
arrest  [41-43].  Thus,  it  is  possible  that  individual 
modifications with a predominant preference for spe-
cific physiological outcomes serve as ‗binary switches‘ 
of  different  cell  fates.  Furthermore,  with  structural 
biological methods, threonine 18 (T18) has been found 
to exert ‗on-off‘-switch role controlling the binding of 
p53 with Mdm2 [44-46]. This suggests that develop-
ment of test methods also influences the determina-
tion  of  the  functions  of  modifications.  However, 
switch-like behavior of the individual modifications is 
mostly  identified  by  mutation  assay.  This  method 
only proves the essentiality but not the sufficiency of 
these modifications in initiating specific effects. So it 
remains to be determined whether there is a simple 
correlation between an individual modification and a 
specific  effect.  In  fact,  another  characteristic  of  the 
modifications  is  their  multi-potency—that  modifica-
tion of one site exerts various effects in different con-
texts and under different stresses, even if the effects 
are  seemingly  conflicting.  For  example,  our  group 
found that p21waf1/cip1, a canonical cell cycle regulating 
gene,  is  activated  by  K373/K382  acetylation  after  a 
specific  histone  deacetylase  inhibitor 
(HDACi)—depsipeptide—is  administered  [47].  This 
finding contradicts previous results that K373 acety-
lation has a preference for proapoptotic genes [40]. Of 
note,  depsipeptide  also  induces  T18  and  S37  phos-
phorylation.  This  specific  combination  pattern  of 
phosphorylation and acetylation is a likely cause of 
the  contrasting  results.  Similarly,  it  is  shown  that 
K120, with a widely accepted transcription-dependent 
apoptotic  activity,  has  a  transcription-independent 
proapoptotic  function  [48].  While  a  transcrip-
tion-dependent  activity  requires  prior  nuclear  accu-
mulation, nuclear export is the prerequisite for tran-
scription-independent apoptotic activity. S315 phos-
phorylation both increases p53 transactivation poten-
tial  through  nuclear  retention,  and  promotes 
Mdm2-dependent  proteolysis  of  p53  [49-51].  This 
raises the question of how a single modification is able 
to choose between two contrasting fates. 
Therefore, an individual modification of p53 is 
far from discriminating p53 isoforms in deciding bio-
logical effects. Instead, certain combinations of modi-
fications can expand the functional scope of individ-
ual  modifications  and  explain  the  results  from  the 
functional  studies.  In  this  respect,  combined  with Int. J. Biol. Sci. 2012, 8 
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other  modifications,  an  individual  modification  can 
exert  various  functions,  which  interprets  the  mul-
ti-potency of the individual modifications. 
Sequential crosstalk among modifications 
 While individual modifications show little sig-
nificance in coordinating the vast pool  of upstream 
stresses and the downstream repertoire of the target 
genes,  crosstalk  among  different  modifications  may 
provide a way to guarantee the complexity of the p53 
network. In normal cells during cell cycle progression, 
a modification cascade of p53 exists. Phosphorylation 
of S9, 15, 20 and 372 peaks during G1, whereas S37 
and S392 phosphorylation peak during G2/M. S37 is 
the only site to be phosphorylated during S phase and 
acetylation  is  mostly  abundant  at  G0  [52].  This 
demonstrates that at homeostasis, p53 modification is 
a  dynamic  and  transient  event  which  may  be  pre-
dicted under controlled conditions. 
 Under stress, p53 is modified more extensively. 
At the center of the p53 activation are acetylation and 
phosphorylation. Phosphorylation of the N terminus 
serves as the initial wave of response to stress, which 
shows strong inter-dependence between one another. 
For example, T18 is phosphorylated in vitro and in vivo 
subject to the prior phosphorylation of S15, which is a 
prerequisite  of  S20  phosphorylation  [36,  53].  Thus, 
N-terminal  phosphorylations  can  be  classified  into 
several clusters. For each cluster, one site is directly 
modified by the kinases, i.e. nucleating sites, whereas 
others are modified followed by the nucleating sites. 
Not only does sequential inter-site dependence exist 
among  the  N-terminal  phosphorylation  sites, 
C-terminal  phosphorylation  sites  are  also  involved 
[54]. Thus, for phosphorylation, inter-site dependence 
and  activation  cascades  set  a  new  level  for  more 
comprehensive and precise coordination of different 
types of stress. 
 Phosphorylation is also influenced by other up-
stream modifications, such as the addition of O-linked 
β-N-acetylglucosamine  (O-GlcNAcylation)  and  poly 
(ADP-ribosylation)  [55-57].  poly  (ADP-rybosylation) 
of  different  nuclear  acceptors  by  poly  (ADP-ribose) 
polymerase  1  (PARP-1)  is  believed  to  be  a  damage 
sensing  modification,  and  thus  may  bridge  the  gap 
between the DNA damage sensing and p53 stabiliza-
tion. Considering the scarcity of the sites subject to 
either O-GlcNAcylation or poly (ADP-rybosylation), 
they  may  merely  exert  subtle  effects  or  perform 
switch-like roles in p53 activation.   
Specific  phosphorylation  patterns  induce  the 
acetylation  of  the  C  terminus  and  initiate  a  phos-
phorylation-acetylation  cascade  [58].  Consistently, 
with the use of specific DNA damage agents, we and 
other  groups  testified  this  hypothesis  [59-61].  This 
suggests that this cascade is generally implicated in all 
circumstances. It is now confirmed that Mdm2, CREB 
binding protein (CBP)/p300 (specific enzymes for the 
acetylation of p53) and p53 form a ternary complex in 
unstressed cell, and phosphorylation of S15, T18 and 
S20 increase p53‘s affinity for CBP/p300 [62]. Phos-
phorylation of the C terminus also differentially in-
fluences  the  acetylation  status.  For  example,  phos-
phorylation of S378 and T377 reduces the acetylation 
of K373, K382 and K320, and phosphorylation of S366 
and T387 enhances the C-terminal acetylation [54, 58]. 
Since  S378  is  constitutively  phosphorylated  in  un-
stressed  cells,  T377  and  S378  phosphorylation  may 
suppress p53 activation through inhibition of acetyla-
tion. Moreover, C-terminal phosphorylation also me-
diates  ubiquitination  by  Mdm2  [51,  63].  Therefore, 
p53 degradation may be accomplished through a se-
ries  of  interlocking  processes,  which  is  initiated  by 
C-terminal phosphorylation [51, 63], relayed by inhi-
bition of C-terminal acetylation and ended  up  with 
the ubiquitination (Figure 2). In addition to acetyla-
tion,  other  modifications  including  mono- 
ubiquitination,  poly-ubiquitination  [64,  65]  and 
ubuiquitin-like modifications  [66], are also included 
in various cascades. 
 Acetylation is the hub of p53 transactivation and 
is  contained  within  a  network  of  various  upstream 
and  downstream  modifications. Loss  of  Set7/9  in 
mouse  embryonic  fibroblasts  cells  (MEFs)  prevents 
acetylation  at  K117,  K317,  K370  and  K379  (human 
homologous  sites  are  K120,  K320,  K373  and  k382), 
suggesting a general effect of K372 methylation on the 
acetylation  status  of  p53  [67].  Consequently,  acety-
lated p53 can recruit coactivators to the binding pro-
moters and mediate the acetylation of histone H4 [68, 
69].  In  addition,  SUMOylation  also  influences  the 
acetylation of the C terminus and illustrates a unidi-
rectional cascade. K386 SUMOylaiton of at least one 
subunit of p53 tetramer inhibits the consecutive acet-
ylation  by  p300/CBP,  whereas  prior  acetylation  by 
p300  remains  permissive  for  the  SUMOylation  ma-
chinery [70]. This demonstrates distinct behaviors of a 
pathway cascading in opposite directions and a coor-
dination  mechanism  of  a  level  higher  than  the  pri-
mary structure of p53.  
Therefore, the modification of p53 is a dynamic 
process  that rapidly relays the sequential signals to 
the final target  during the course of p53 activation. 
(Summarized in Figure 2). 
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Figure 2. Summary of the sequential interplay of modifications of p53. This figure shows the modification cascades which can 
be classified into short-range and long-range influences, which is reminiscent of the model raised by X-J Yang [127]. In addition, effects on 
the downstream modification sites can be either negative (indicated by arrows with a ‘-’ in a circle) or positive (indicated by arrows with 
a ‘+’ in a circle). According to the sequential order of the modifications, they are crudely classified into two cassettes. Modifications in the 
initializing cassette are responsible for the sensing and distinguishing of the stresses and can transmit the signals to the functional cassette. 
Modification combinations in the functional cassette can induce specific biological outcome. 
 
Spatial crosstalk among the modifications 
In addition to sequential crosstalk, there is also 
spatial crosstalk among the PTMs, which is charac-
terized by combinations of multisite modifications to 
trigger p53 response cooperatively (i.e. combinatorial 
behaviors). Series of combinatorial behaviors of dif-
ferent modifications on other proteins  have already 
been characterized, including Forkhead Box protein O 
(FoxO)  family  [71-74],  tubulin  and  the  C-terminal 
domain  of  RNA  polymerase  II  [75,  76].  Analogous 
with  the  interplay  of  histone  modifications  and  the 
none-histone protein modifications [77, 78], p53 mod-
ifications also demonstrate spatial crosstalk. The sim-
plest behavior is the competition of the same site by 
different  kinds  of  modifications.  Mostly  influenced 
are lysines located in the CTD of p53, especially the 6 
lysines acetylated by p300/CBP and K320 acetylated 
by P300/CBP-associated factor (PCAF). All the acet-
ylation sites are ubiquitination targets [79], with some 
of  them  competing  with  methylation,  SUMOylation 
and  neddylation,  suggesting  mutual  exclusivity  of 
these modifications. Moreover, functions of the mod-
ifications  of  the  same  sites  vary  according  to  the 
number  of  moieties  added.  This  is  exemplified  by 
methylation of K370, K373 and K382 [80-82] and the 
competitive mono- and polyubiquitination of several 
lysines in the C terminus [83]. Besides the competition 
for  the  same  amino  acid,  crosstalk  among  adjacent 
sites in the primary amino acid sequence or higher 
order  structure  of  protein  also  exists.  The  spatial 
crosstalk has both antagonistic and synergistic effects. 
Antagonism is exemplified by the interplay of modi-
fications on the CTD, such that methylation of K370 
and K372 and phosphorylation of S315 and S392 occur 
in a mutually exclusive way [84, 85]. Synergy is char-
acterized by the sites functioning or modified simul-
taneously.  As  shown  in  Figure  3,  the  key  problem 
resolved  by  this  hypothesis  is  the  multisite  phos-
phorylation of the N terminus. The multiplicity may 
indicate the need for a critical amount of phosphory-
lation sites to reach an activation threshold, forming a 
multisite switch, which is reminiscent of the regula-
tion of Ste5 by cyclin-cyclin dependent kinase com-
plex  (Cln/CDK)  [86].  In  addition,  simultaneous 
phosphorylation  and  acetylation  of  several  sites  is 
essential for the interaction of p53 with Pin1 and TAF1 
respectively [87, 88]. Apart from addition of covalent 
moieties, deletion is also indispensable. For example, 
simultaneous phosphorylation of S378, S366 and T387 
and dephosphorylation of S376 results in p53 tetram-
erization and transcriptional activation [89-91]. Int. J. Biol. Sci. 2012, 8 
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Figure 3. Generalization of the synergistic manner of different modifications and their binding partners. The functions of 
the p53 modifications are mutually dependent. A given combination of modifications can exert their specific functions simultaneously, and 
a specific binding partner, usually protein, mediates the function of modifications. Dashed lines and questions marks highlight that these 
modifications are likely to function synergistically. 
 
 
Based on the established cooperative manners of 
modifications,  lots  of  other  modifications  are  pre-
dicted  to  perform  synergistically.  Multi-
site-monoubiquitination that was previously thought 
to function redundantly, now seems to strengthen the 
binding  affinity  between  proteins  [92-94].  Likewise, 
methylation of three arginines in the C terminus may 
also  perform  simultaneously  [95].  Furthermore,  the 
dual modification pattern in the interaction between 
14-3-3 and histone through phospho-acetylation [96] 
is indicative of the interaction between 14-3-3 and p53. 
Apart  from  the  established  role  of  K370  and  K382 
di-methylation [80, 81] in the interaction between p53 
and p53 binding protein 1 (53BP1), phosphorylation 
shows  great  potential  to  be  involved  [97-100].  Fur-
thermore,  motifs  which  can  associate  with  several 
modifications  and  proteins  with  multiple  modifica-
tion-recognizing motifs have also been characterized 
[101]. On the whole, protein-protein interactions ap-
pear to underlie the majority of cooperative regula-
tions by modifications. 
Both sequential and spatial crosstalk represents 
combinatorial performance of covalent modifications. 
Due to this combinatoriality, the selectivity and vari-
ability of p53 functions are yielded.  
Regulation mechanisms by PTMs 
 PTM cascade of p53 is always accompanied by a 
binding partner cascade, indicating a role of the mod-
ifications to mediate the interaction between p53 and 
its partners. This has raised tantalizing questions of 
how the interactions are regulated. In fact, there are 
various  underlying  mechanisms  for  the  interaction 
which should be discussed. 
Conformational changes 
Conformation is the most important  feature of 
protein structure, which dramatically influences the 
function of the protein. Since PTMs can elicit signifi-
cant  effect  on  protein  function  through  conforma-
tional  changes  [102-104],  different  combinations  of 
PTMs  may  yield  distinct  protein  conformations,  re-
sulting in the ensuing specific interaction [76]. 
As for p53, modification confirmed to influence 
its  conformation  is  the  phosphorylation-dependent 
isomerization by Pin1 [105], which is supported by the 
fact that p53 needs to form a complex with Pin1 to 
exert its functions  [87, 105, 106]. This indicates that Int. J. Biol. Sci. 2012, 8 
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other modifications of p53 may also show great po-
tential  in  converting  PTMs  into  conformational 
changes. 
 p53  CTD  can  either  positively  or  negatively 
regulate p53‘s transactivation ability, and its acetyla-
tion can potentiate p53 sequence-specific binding in 
vitro  [19,  107,  108].  The  underlying  mechanism  for 
sequence-specific binding was suggested to be allo-
steric activation [19, 58, 109], which either exposes the 
DNA binding domain (DBD) of p53, or influences the 
interaction  between  other  proteins.  DBD  of  p53 
mainly mediates its direct binding with its consensus 
sequence and is heavily influenced by conformation. 
This is consolidated by the structural study revealing 
that  p53  sequence-specific  binding  involves  a  con-
formational switch in its DBD [110]. Unlike DBD of 
FoxO  family  whose  binding  affinity  is  substantially 
influenced  by  its  phosphorylation  and  acetylation 
[111],  DBD  of  p53  shows  poor  access  for  covalent 
modifications.  However,  since  the  mechanism  for 
K164 and K120 acetylation of p53 remains unclear, a 
conformational change similar to FoxO may cause this 
effect.  Likewise,  ubiquitination,  especially 
mono-conjugated,  shows  great  potential  to  regulate 
p53 conformation, possibly owing to its function as a 
chaperone  to  promote  folding  of  nascent  proteins 
[112]. 
 Conformation is closely related to the energy of 
the  molecule  and  serves  as  a  major  regulator  of 
backbone structure. By virtue of the conformational 
change, the otherwise buried docking sites or catalytic 
sites can be exposed and thus induce the interaction 
between  proteins,  DNA  and  chromatin.  Since  these 
modifications  can  induce  significant  structural 
changes, they may serve as simple ‗on/off‘ switches 
to regulate the qualitative responses of p53. However, 
as  have  been  suggested,  conformational  changes 
cannot be incorporated into specific kind of protein 
during evolution, which limits the generality of this 
mechanism [101]. 
Combinations of docking motifs 
Histone  tails  are  heavily  modified  and  can  be 
read  by  effector  proteins  through  direct  binding.  It 
was hypothesized that this effect is mediated by the 
covalent  modifications  embedded  in  specific  motifs 
[113]. In support of this hypothesis, protein modules 
specific for recognizing modifications on histone tails 
are identified. These include bromodomain [114, 115], 
chromodomain [116, 117] and the more recent plant 
homeodomain (PHD) [118-121], Tudor and MBT [122] 
domains. Furthermore, it is confirmed that a protein 
can contain more than two modification recognition 
domains [123-125], and some protein complexes can 
embrace subunits with distinct modification recogni-
tion motifs. This provides a novel way to recognize 
cooperatively the modification signals [126].  
The functions of non-histone protein modifica-
tions can be extrapolated from the histone modifica-
tions. Consistently, protein modules that specifically 
recognize modifications on non-histone proteins are 
characterized  [127].  Together  with  the  flanking  se-
quences, modifications can mediate specific binding 
of  p53  with  the  modification  recognizing  modules 
(summarized  in Table 1). Therefore, docking motifs 
appear to be a precise commander enabling dynamic 
and specific binding of p53 with other partners.  
 
Table 1. Modifications as docking motifs and their binding proteins. 
Modification  Sites  Binding protein  domain  Reference 
phosphorylation  S46, S33, T81, S127,  
T150, S315 
Pin1  WW  Ref 105 
dephosphorylation  S376  14-3-3    Ref 95 
acetylation  K382  P300/CBP  bromo  Ref 159 
di-acetylation  K373, K382  TAF1  Tadem bromo  Ref 88 
SUMOylation  K386    SIM  Ref 160, 161 
di-methylation  K382, K370  53BP1  Tudor  Ref 80, 81 
Ubiquitination      UBD  Ref 83, 162 
monomethylation  K382  L3MBTL1  MBT  Ref 163 
K372  Tip60  Chromo  Ref 67 
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Bulk electrostatics 
Intrinsically  disordered  regions  of  proteins 
which are quite frequent in nature perform important 
functions in cells [128]. These regions always serve as 
the linkers between different domains of the proteins. 
There are three unstructured regions in p53: the linker 
between  N-terminal  transactivation  domain  (TAD) 
and DBD, the linker between DBD and TD, and CTD 
[129, 130].  
Many  kinds  of  modifications,  including  phos-
phorylation,  acetylation  and  ADP-ribosylation,  can 
change the overall charge of the amino acid residues, 
and  in  turn  contribute  to  the  electrostatic 
force-mediated interactions [131]. The first to be men-
tioned is the multisite phosphorylation of the TAD of 
p53 which mediates the binding with p300/CBP. Ra-
ther than a switch-like behavior, an additive manner 
of phosphorylations of S15, S20, T18, S46, S33, S37 and 
T55 was demonstrated [45]. In this scenario, the elec-
trostatic  forces  generated  by  negative  charges  of 
phosphate and the positive charge of CBP contribute 
to the interaction. In addition, p53 transcriptional ac-
tivity can exhibit both on/off switch and graded re-
sponse  after  genotoxic  stress  [132].  An  extension  of 
this  fact  is  that  the  seeming  redundancy  of  the 
N-terminal  phosphorylation  can  contribute  to  the 
graded response. The redundancy may also play crit-
ical  roles  in  sensing  the  nature  and  the  severity  of 
cellular stresses, whereby prolonged or severe geno-
toxic  stress  leads  to  phosphorylation  of  additional 
sites  and  gradual  increase  in  the  affinity  for 
CBP/p300.  Apart  from  the  TAD,  modifications  of 
lysines on CTD, especially the acetylation of the six 
lysines in proximity, may also neutralize the positive 
charge on CTD [19]. Other models of multisite acety-
lation  functioning  as  charged  patches  have  already 
been  established,  including  histone  acetylation  and 
p300 autoacetylation [133, 134]. These models further 
increase  the  possibility  of  the  acetylation  on  p53‘s 
CTD to function as electrostatic regulator. 
 The  bulk  electrostatic  mechanism  explains  the 
graded  response  of  p53  and  confers  a  quantitative 
feature  on  p53  response.  However,  since  various 
modifications  share  the  same  electric  property,  this 
mechanism is not precise enough. Hence, structure of 
different  kinds  of  moieties  is  necessary  in  distin-
guishing different modifications. 
 The three mechanisms presented above function 
cooperatively.  The  conformational  switch  regulates 
the rigid backbone of p53‘s globular regions and ex-
poses  the  docking  motifs  for  interaction  proteins. 
Docking motifs, in turn, directly coordinate the bind-
ing of p53 with its partners through interacting with 
specific  modification  recognizing  modules.  Electro-
static forces increase the binding efficiency by specif-
ically utilizing the flexibility of the unstructured re-
gions. Henceforth, modifications inducing conforma-
tional  changes  behave  as  ‗on/off‘  switches  toggling 
between different subsets of p53 events through ex-
posure of different groups of docking motifs. Specific 
docking motifs serve as combinatorial signals to re-
cruit  binding  partner.  Modifications  regulating  the 
electrostatic attraction yield a rheostat behavior of p53 
to quantitatively coordinate the events like a sensor or 
blocker.  In  consequence,  these  mechanisms  form  a 
complex and precise coordination network for p53. 
Deciphering the ‘p53 code’ 
 Spatial and sequential interplay of p53 modifi-
cations provides it with vast indexing potential and 
expands  its  functional  spectrum.  A  semiotic  view, 
such as ‗code‘, ‗barcode‘ or ‗cassette‘, is adopted to 
define the complex network among the modifications 
of both histones and non-histone proteins [40, 135]. In 
this  semiotic  system,  several  elements,  including 
code, regulator and the ‗meaning‘ of the code are in-
dispensable. Regulators can be classified into ‗reader‘, 
‗writer‘ and ‗eraser‘ (see Figure 4). ‗Reader‘ refers to 
binding partner  like chromatin,  non-histone protein 
and DNA that interacts specifically with the modifi-
cation marks and initiates specific effects.  These in-
clude conformational changes, catalytically activation 
and transcriptional activation. Protein adding chemi-
cal groups to specific sites is defined as ‗writer‘; by 
contrast,  ‗eraser‘  is  responsible  for  the  removal  of 
chemical group from specific sites. However, there are 
no  strict  divisions  between  the  definitions  of  these 
regulators;  a  protein  can  have  multiple  properties 
such that the process of reading and writing can be 
completed by the same protein. These regulators in 
the semiotic system are coordinated either at protein 
level or, more precisely, at the posttranslational level. 
Specific  modification  at  particular  sites  can  distin-
guish between different forms of a protein and guar-
antee the functional specificity of the regulators. Basic 
to p53 degradation is Mdm2, of which the most rele-
vant modifications are autoubiquitination [136, 137], 
phosphorylation  [138-142],  SUMOylation  [143,  144] 
and acetylation [145]. Similar to Mdm2, other ubiqui-
tin  ligases  including  Pirh2  [146]  and  constitutively 
photomorphogenic  1  (COP1)  are  also  subject  to  the 
regulation by PTMs [147]. 
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Figure 4. Diagram of the p53 ‘code system’. At homeostasis, p53 is mainly presented in two forms: chromatin-bound (b) form and 
unbound form (c). Under stress, p53 is modified combinatorially by various enzymes. Thus, the ‘code’ is written (a). Specific ‘code’ on 
chromatin-bound p53 can recruit either histone modifying enzymes (d), histone remodelers (e) or other regulatory proteins (f) to the 
vicinity of the response element p53 is bound to. As for the unbound form, DNA with p53-binding sites (g) and other enzymes (h) 
recognize the code. Different ‘readers’ lead to distinct outcomes. Modifications of histones, remodeling of chromatin, directly activation 
or repression of transcription, conformational changes as well as extensive modifications of p53 are the effects of histone modifying 
enzymes, histone remodelers, additional regulatory proteins, specific DNA sequences and other enzymes, respectively. 
 
 
 histone  acetyltransferase  (HAT)  and  histone 
deacetylase (HDAC) regulate acetylation of both his-
tones and transcription factors, yielding a connection 
between  chromatin  accessibility  and  transcription 
activity. p300 and CBP are coactivators for a variety of 
transcription factors, whose activation is mainly reg-
ulated by autoacetylation [134, 148]. Similarly, we and 
other groups also found that class III HDACs sirtuins, 
especially  SIRT1  and  SIRT7  participating  the 
deacetylation of p53, are phosphorylated and meth-
ylated [149-151]. Notably, different proteins modified 
by  the  same  enzyme  can  function  either  synergisti-
cally to enhance the overall effects, or antagonistically 
to create a delicate balance [152]. This well explains 
the inconsistencies in the in vitro and in vivo experi-
mental results: the in vitro methods used may always 
disturb  the  stoichiometry  between  different  targets 
subject to same modifications. 
 Another  critical  element  within  this  semiotic 
system of p53 is the interpretation of the code. ‗PTM 
code‘  of  non-histone  proteins  [153]  is  originally  ex-
trapolated from the ‗histone code‘, [77, 78] which is 
interpreted as ‗transcription starts or stops at a spe-
cific  time  and  place‘  [154].  Although  there  are  still 
arguments against the code‘s generality considering 
the  context-dependent  meaning  and  the  weak  pre-
dictability  of  modifications  themselves  [113],  exten-
sive  combinations  of  modifications  strengthen  the 
specificity  and  more  clearly  define  the  concepts  of 
‗code‘. The meaning of the ‗code‘ of p53 modification 
can  be  interpreted  as  the  functions  of  interaction 
partners—including non-histone proteins, histones as Int. J. Biol. Sci. 2012, 8 
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well as DNA—encoded combinatorially by the modi-
fications  (Figure  4).  PTMs  on  the  regulators  can  be 
translated into anti-code matching with specific code 
on p53. In this way, only the properly modified regu-
lators can recognize a specific form of p53. More re-
cently, as revealed by the interdependence between 
p53 modifications and histone H3 modifications [155, 
156],  a  ‗p53-histone‘  code-to-code  model  connecting 
the histone and non-histone modifications has been 
raised. 
With  respect  to  this  semiotic  system,  a 
stress-specific performance of p53 can be explained by 
the differences of modification marks induced by dis-
tinct  stresses  [157].  Likewise,  cell-  and  tissue-type 
dependency of p53 behavior can be attributed to spe-
cific combinations of p53 modifications introduced by 
intrinsically distinct regulator pools in different types 
of cells or tissues [158]. Furthermore, a modification 
cascade can serve as a driving force for p53 pathway 
to  progress  spontaneously,  which  indicates  a  more 
general regulating rationale for other signaling path-
ways. 
Future perspectives 
 Promising as the ‗code‘ model of p53 PTM is, the 
following questions remain open such as: what is the 
real basis for the redundancy of the individual modi-
fications  in  vivo?  What  is  the  real  mechanism  that 
regulates  the  context-dependent  behavior  of  p53? 
How exactly is p53 involved in the regulation of one 
specific biological effect? How general is the mecha-
nism for the regulation of PTM and in what way do 
they  really  cooperate?  With  the  emergence  of  the 
novel functions regulated by p53, such as metabolism 
and nutrient stress responses, is there a possibility to 
revise the demarcations between different phenotypic 
outcomes  to  a  more  subtle  one?  In  order  to  tackle 
these problems, numerous further investigations are 
required: (i) more precise and subtle distinction of the 
effects  of  the  ‗code‘  in  molecular  level  instead  of 
phenotypic level; (ii) discrimination between the di-
rect and indirect effects of specific modifications; (iii) 
identification  of  the  combinatorial  behaviors  of  the 
modifications using high-throughput testing method; 
(iv) in situ observation of the dynamic changes of the 
modifications  marks  using  more  reliable  and  direct 
time-resolved method. Although there is still a long 
way to go, it is believed that the final decipherment of 
the p53 code will arrive in the near future. 
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